Contemporary cost‐effectiveness analysis comparing sequential bacillus Calmette‐Guerin and electromotive mitomycin versus bacillus Calmette‐Guerin alone for patients with high‐risk non–muscle‐invasive bladder cancer

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|120|16|2424-2431

ISSN: 0008-543x

Source: CANCER, Vol.120, Iss.16, 2014-08, pp. : 2424-2431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content